Navegando por Palavras-chave "bradicardia"

Agora exibindo 1 - 1 de 1
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis
    (Academia Brasileira de Neurologia - ABNEURO, 2014-09-01) Fragoso, Yara Dadalti; Arruda, Christian Cardoso; Arruda, Walter Oleschko; Brooks, Joseph Bruno Bidin; Damasceno, Alfredo; Damasceno, Carlos Augusto de Albuquerque; Finkelsztejn, Alessandro; Finkelsztejn, Juliana; Gama, Paulo Diniz da; Giacomo, Maria Cristina Brandão; Gomes, Sidney; Goncalves, Marcus Vinicius Magno; Matta, Andre Palma da Cunha; Morais, Marilia Manprim de; Oliveira, Enedina Maria Lobato de [UNIFESP]; Ribeiro, Yuna; Sato, Henry Koiti; Tauil, Carlos Bernardo; Universidade Metropolitana de Santos Departamento de Neurologia; Universidade Positivo Departamento de Neurologia; Universidade Federal do Paraná Departamento de Neurologia; Universidade Estadual de Campinas (UNICAMP); Universidade Federal de Juiz de Fora Departamento de Neurologia; Hospital de Clínicas de Porto Alegre Departamento de Neurologia; Pontifícia Universidade Católica Sorocaba Departamento de Neurologia; Clínica Holus MedService; Hospital Beneficência Portuguesa de São Paulo Departamento de Neurologia; Centro Hospitalar Unimed Departamento de Neurologia; Universidade Federal Fluminense Departamento de Neurologia; Universidade Federal de São Paulo (UNIFESP); Hospital de Base do Distrito Federal Departamento de Neurologia; Instituto de Neurologia de Curitiba Departamento de Neurologia
    Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.